Prevalence of diabetes mellitus and metabolic syndrome in prostate cancer patients given Androgen Deprivation Therapy

Maria Luisa Cecilia Rivera-arkoncel; Michael Sagun; Francis Raymond Arkoncel; Cecilia Jimeno; Marie Carmela Lapitan

Return

Prevalence of diabetes mellitus and metabolic syndrome in prostate cancer patients given Androgen Deprivation Therapy

Author: Maria Luisa Cecilia Rivera-Arkoncel ¹ ; Michael Sagun ² ; Francis Raymond Arkoncel ² ; Cecilia Jimeno ¹ ; Marie Carmela Lapitan ²
Author Information

1. Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of the Philippines- Philippine General Hospital
2. Division of Urology, Department of Surgery, University of the Philippines- Philippine General Hospital
Publication Type:Journal Article
Keywords: Androgen deprivation therapy
MeSH: Prostatic Neoplasms; Diabetes Mellitus; Metabolic Syndrome
From: Journal of the ASEAN Federation of Endocrine Societies 2014;29(1):42-47
CountryPhilippines
Language:English
Abstract: Objective:To compare the prevalence of diabetes mellitus (DM) and metabolic syndrome (MetS) in prostate cancer patients with or without androgen deprivation therapy (ADT).
Methodology:This is a cross-sectional analytic study of prostate cancer patients from the Integrated Surgical Information System database of the Philippine General Hospital from 2004-2010. Patients who received either continuous monthly GnRH agonist injection for at least 6 months or underwent bilateral orchiectomy at least 6 months prior (ADT group) were compared to those who did not (non-ADT group). Patients with DM and MetS were identified using the American Diabetes Association Standards of Medical Care in Diabetes 2010 and IDF Definition of Metabolic Syndrome.
Results:The prevalence of DM in the ADT group is 42% and 19% in the non-ADT group (p = 0.0460). The probability of having DM is 2.17x higher among prostate cancer patients who received ADT compared to those who did not. The prevalence of metabolic syndrome in the ADT and non-ADT group is 37% and 28%, respectively (p=0.4620).
Conclusions:Prostate cancer patients have become an important emerging population of medically at risk older men. Our study showed that the prevalence of DM is significantly higher among the ADT group, with a trend towards greater prevalence of metabolic syndrome in the same group. These men may benefit from closer monitoring for the development of these metabolic complications.
Full text:114-Article Text-553-1-10-20140531.pdf